Partnerships with fellow nonprofits in dermatology and psoriasis allow us to share our knowledge, collaborate on important projects, and collectively advocate for improved treatment of patients worldwide.
The International Federation of Psoriasis Associations (IFPA) is a non-profit organization uniting national and regional psoriasis associations from around the world.
Officially founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health around the world for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology. Today, the ILDS represents dermatology at the highest level with over 170 Member Societies from more than 80 countries, we represent over 150,000 dermatologists.
Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education and patient/family care.
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
UPCOMING EVENT The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory? Wednesday, September 18, 2019 2:00 pm - 6:00 pm Bordeaux, france Register Now
IPC Psoriasis Review Newsletter IPC's bi-annual review of the latest manuscripts in the field of psoriasis. Read the latest issue
IPC's bi-annual review of the latest manuscripts in the field of psoriasis.
Psoriasis News Announcing IPC's Newest Corporate Partner: Ortho Dermatologics9/3/2019 11:11:00 AM Get Connected: World Psoriasis Day 20199/3/2019 9:41:00 AM In Memory of Gladys León Dorantes9/2/2019 3:24:00 PM Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council8/29/2019 7:13:00 AMPsoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, due to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be mis-categorized, which can lead to under-treatment of psoriasis. More News